1. Hepatitis B virus reactivation in HBsAg-negative patients is associated with emergence of viral strains with mutated HBsAg and reverse transcriptase
- Author
-
Anne Motte, Catherine Tamalet, René Gerolami, D. Botta-Fridlund, Aude Charbonnier, Patrick Borentain, Julie Bertrand, Diane Coso, Jacques Serratrice, Isabelle Portal, Thérèse Aurran-Schleinitz, Anne-Marie Stoppa, Fabrice Barlesi, Mélanie Serrero, Christian Chabannon, and Philippe Colson
- Subjects
Adult ,Male ,Hepatitis B virus ,HBsAg ,Hepatitis B virus DNA polymerase ,Antineoplastic Agents ,Biology ,medicine.disease_cause ,Hepatitis B virus PRE beta ,Serology ,Neoplasms ,Virology ,HBV therapy ,medicine ,Chemotherapy ,Humans ,HBV-DNA detection ,Aged ,Hepatitis B virus reactivation ,Hepatitis B Surface Antigens ,Nucleoside analogue ,virus diseases ,RNA-Directed DNA Polymerase ,Middle Aged ,Resistance mutation ,digestive system diseases ,Reverse transcriptase ,Female ,Mutant Proteins ,Virus Activation ,medicine.drug - Abstract
Background/aims Virological factors associated with hepatitis B virus reactivation (HBV-R), following chemotherapy for cancer in hepatitis B surface antigen (HBsAg)-negative patients, are not well known. Materials and methods HBV strains from 16 patients presenting HBV-R following chemotherapy were studied and compared to those obtained from 51 HBV chronically-infected patients. Results HBsAg variability was significantly increased within the major hydrophilic region, the a determinant and the C-terminal region. Amino acid substitutions were more frequently found in HBV-R patients as compared to controls at 17 and 11 positions within HBsAg and HBV-RT, respectively. This resulted in atypical serological testing in 56% of patients and detection of resistance mutation to nucleoside analogs in 12.5%. Conclusion HBsAg and HBV-RT mutations are frequently encountered in patients with HBV-R, resulting in atypical serological testing and emergence of HBV strains resistant to nucleos(t)ides analogs.
- Published
- 2015